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The issue of limiting life-sustaining treatments for
intensive care unit (ICU) patients is complex. The
ethical principles applied by ICU staff when making
treatment-limitation decisions must comply with the
law of their country. Until 2011, the law in Taiwan
prohibited the withdrawal of mechanical ventilation.
Consequently, patients with severe underlying
diseases could receive prolonged mechanical
ventilation. In a study conducted by Shih and
colleagues in patients with cancer in Taiwan,
continuous mechanical ventilation for more than 21
days was associated with poor outcomes, particularly
in the subgroups of patients with metastases, lung
cancer, or liver cancer. These results highlight the
need for appropriate legislation regarding the
withdrawal of life-sustaining treatments in patients,
especially those for whom no effective cancer
treatments are available.of solid malignancies are available. Unlike in most otherIn the previous issue of Critical Care, Shih and col-
leagues [1] report the results of a claims database study
in 5,138 cancer patients who received prolonged mech-
anical ventilation (PMV) in Taiwan between 1997 and
2007. The authors describe the incidence, outcomes, and
prognostic factors of PMV in this cohort. PMV was de-
fined as at least 21 days of continuous mechanical venti-
lation. Most of the patients survived the acute illness but
required a disproportionate amount of health-care re-
sources [2]. The incidences of PMV were 10.4 patients
per 100 intensive care unit (ICU) admissions with cancer
overall and 14.9 per 100 admissions of patients with lung* Correspondence: atoffart@chu-grenoble.fr
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© 2013 BioMed Central Ltd.cancer. The prognosis was poor: 1-year survival rate was
14.3% (95% confidence interval 13.3% to 15.3%). Survival
rate and life expectancy were worse in the subgroups
with metastases, lung cancer, or liver cancer. As previ-
ously reported, mortality was dependent mainly on
metastatic status and acute organ failure (acute renal
failure or shock). Moreover, quality-adjusted life expect-
ancy (QALE) was poor, ranging from 0.18 to 0.48 quality-
adjusted life-years (QALYs) in patients in the best
cognitive-function category. The same team previously
[3] estimated the cost of PMV at USD $64,708 to USD
$148,829 per QALY for patients with cancer.
This study is original because it estimates the benefits
of maximal treatment intensity in patients with cancer.
In Taiwan, mechanical ventilation withdrawal, which
may affect life expectancy [4], was illegal at the time of
the study period. This is the first study on PMV for pa-
tients with cancer and the largest to investigate patients
with cancer in the ICU. Furthermore, no previous data
on outcomes of critically ill patients with different types
studies in critically ill patients with cancer, solid malig-
nancies predominated (94% of patients).
However, the data were extracted from a national
health insurance database designed for cost evaluations
and not for research purposes. A number of weaknesses
of the study should be acknowledged. No data were
available on the reason for ICU admission, severity of
the acute disease, or performance status. Noninvasive
mechanical ventilation and invasive mechanical ventila-
tion were not distinguished from one another, and nei-
ther were intubation and tracheostomy. Furthermore,
QALE was estimated by extrapolation from an external
sample of 142 unselected ICU patients given PMV [3],
and this fact may not be fully relevant to patients with
cancer. The low QALE estimated for the first year was
probably an underestimation of the overall quality of life
during long-term survival, since quality of life has been
reported to improve after 1 year in long-term survivors [5].
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cer treated with mechanical ventilation, particularly in
those with solid malignancies. Differences have been
reported according to the type of cancer. In lung cancer
patients admitted to the ICU, 1-year survival was esti-
mated to be 18% [6], versus 6.6% in the present study
[1]. Mechanical ventilation for more than 96 hours af-
fected quality of life and functional status but had no
significant effect on survival in earlier studies [7,8]. In a
multicenter hospital-discharge study in the US, mechan-
ical ventilation for more than 96 hours, for any reason,
resulted in higher hospital costs (USD $40,903 versus
USD $14,434) with similar survival compared with
shorter mechanical ventilation durations [8]. Similarly,
among patients with cancer in a multicenter study from
Brazil, including 91% given mechanical ventilation at
ICU admission, hospital and 6-month mortality rates in
those who spent more than 21 days in the ICU (50% and
60%, respectively) were similar to those in patients with
shorter ICU stays (51% and 61%, respectively) [9]. In
two other studies, no patients survived after being
started on mechanical ventilation at least 3 days after
ICU admission [10,11].
The prognostic factors in cancer patients admitted to
the ICU are related to the history of the cancer, the con-
dition of the patient, acute disease, and treatment-
limitation decisions [4,12]. The current evidence sup-
ports ICU admission of patients with cancer for a period
of full-code management followed by a reappraisal of
the situation after 3 to 5 days [13]. Thus, many studies
have established that clinical deterioration during the
first days of mechanical ventilation predicts futility of
further mechanical ventilation [6,14]. Shih and col-
leagues [1] showed, in contrast, that stabilization or im-
provement after the first 3 days is not associated with
higher mortality rates after PMV. However, PMV may
result in a high risk of quality-of-life impairments. This
point underlines the importance of having the patient
and family participate in the treatment decisions.
Overall, PMV was beneficial in 14% of the cancer pa-
tients studied by Shih and colleagues [1]. However, the
main characteristics of these patients are unknown. Fur-
ther studies are warranted to determine which patients
are likely to benefit from PMV according to their per-
formance status, cancer history, and acute disease.
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